Literature DB >> 20587242

Treatment for intracranial cerebral artery stenosis.

K Kawaguchi1, T Kubo, H Takeuchi, S Nemoto.   

Abstract

SUMMARY: Symptomatic intracranial cerebral artery stenosis is largely resistant to drug treatment. Regardless of their locations, lesions may cause cerebral infarction with a frequency of 7-10% in a year, but the natural history of asymptomatic intracranial cerebral artery stenosis remains unclear. Revascularization is indicated for symptomatic lesions which show resistance to drug treatment, while bypass surgery is the accepted therapeutic indication for haemodynamic ischemia. Endovascular treatment is effective in haemodynamic ischemia, and is also expected to be effective against embolic symptoms. Bypass surgery for anterior circulation cases is safe because of its low incidence of complications, whereas bypass surgery for posterior circulation cases is technically difficult and has a high associated complication rate. Hence, endovascular treatment is currently favored for posterior circulation cases, and has also been introduced for anterior circulation cases. Endovascular treatment has become a widespread modality for intracranial cerebral artery stenosis, but there are many unsolved problems associated with complications, technology and devices. Therefore, in practice, endovascular treatment should be used only with a strict indication, and should be performed only after considerable thought and with appropriate informed consent.

Entities:  

Year:  2008        PMID: 20587242      PMCID: PMC3522213          DOI: 10.1177/15910199040100S203

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  8 in total

1.  Endovascular therapy for stenosis of the petrous or cavernous portion of the internal carotid artery: percutaneous transluminal angioplasty compared with stent placement.

Authors:  Tomoaki Terada; Mitsuharu Tsuura; Hiroyuki Matsumoto; Osamu Masuo; Tomoyuki Tsumoto; Hiroo Yamaga; Toru Itakura
Journal:  J Neurosurg       Date:  2003-03       Impact factor: 5.115

2.  Superficial temporal and occipital artery bypass pedicles to superior, anterior inferior, and posterior inferior cerebellar arteries for vertebrobasilar insufficiency.

Authors:  J I Ausman; F G Diaz; D F Vacca; B Sadasivan
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

3.  Progression and clinical recurrence of symptomatic middle cerebral artery stenosis: a long-term follow-up transcranial Doppler ultrasound study.

Authors:  J F Arenillas; C A Molina; J Montaner; S Abilleira; M A González-Sánchez; J Alvarez-Sabín
Journal:  Stroke       Date:  2001-12-01       Impact factor: 7.914

4.  Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up.

Authors:  J E Sousa; M A Costa; A C Abizaid; B J Rensing; A S Abizaid; L F Tanajura; K Kozuma; G Van Langenhove; A G Sousa; R Falotico; J Jaeger; J J Popma; P W Serruys
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

5.  Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial.

Authors: 
Journal:  N Engl J Med       Date:  1985-11-07       Impact factor: 91.245

6.  Comparison of periprocedure complications resulting from direct stent placement compared with those due to conventional and staged stent placement in the basilar artery.

Authors:  Elad I Levy; Ricardó A Hanel; Alan S Boulos; Bernard R Bendok; Stanley H Kim; Kevin J Gibbons; Adnan I Qureshi; Lee R Guterman; L Nelson Hopkins
Journal:  J Neurosurg       Date:  2003-10       Impact factor: 5.115

7.  Intracranial internal carotid artery stenosis.

Authors:  D R Craig; K Meguro; C Watridge; J T Robertson; H J Barnett; A J Fox
Journal:  Stroke       Date:  1982 Nov-Dec       Impact factor: 7.914

8.  Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group.

Authors: 
Journal:  Stroke       Date:  1998-07       Impact factor: 7.914

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.